Unveiling 4 Analyst Insights On Metagenomi
Portfolio Pulse from Benzinga Insights
In the past three months, four analysts have provided ratings on Metagenomi (NASDAQ:MGX), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $12.25, down from a previous $14.75. Analysts have adjusted their ratings and price targets in response to market conditions, with some lowering their targets. Metagenomi, a genetic medicines company, has shown significant revenue growth but lags behind industry peers. The company maintains a strong financial position with effective debt management.

August 21, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Metagenomi (NASDAQ:MGX) has received mixed analyst ratings, with a lowered average price target of $12.25. The company shows strong revenue growth but lags behind peers, maintaining a solid financial position with effective debt management.
The article discusses recent analyst ratings for Metagenomi, highlighting a decrease in the average price target and mixed sentiments. Despite strong revenue growth, the company lags behind peers, which may neutralize the impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100